rabi
acut
fatal
neurolog
diseas
affect
almost
kind
mammal
vaccin
use
inactiv
rabi
vaccin
combin
administr
rabi
immun
globulin
approv
effect
method
postexposur
prophylaxi
rabi
human
search
novel
rabi
control
treatment
strategi
liveattenu
virus
recent
emerg
practic
promis
approach
immun
control
rabi
unlik
convent
inactiv
rabi
vaccin
liveattenu
virus
genet
modifi
virus
abl
replic
inocul
recipi
without
caus
advers
effect
still
elicit
robust
effect
immun
respons
rabi
viru
infect
number
virus
intrins
capac
could
use
put
candid
liveattenu
rabi
vaccin
intens
evalu
therapeut
purpos
addit
novel
strategi
monoclon
antibodybas
approach
nucleic
acidbas
vaccin
small
interf
rna
sirna
interf
viru
replic
could
add
arena
strategi
combat
rabi
review
highlight
current
advanc
rabi
therapi
discuss
role
might
futur
rabi
treatment
given
pronounc
complex
impact
rabi
patient
combin
novel
modal
potenti
achiev
maxim
antirabi
efficaci
may
even
promis
cur
effect
futur
howev
sever
hurdl
regard
clinic
safeti
consider
public
awar
overcom
approach
ultim
becom
clinic
relev
therapi
expos
surfac
viru
major
determin
viral
pathogen
also
major
protect
antigen
respons
induc
protect
immun
rabi
fortun
rabi
vaccineprevent
diseas
provid
postexposur
prophylaxi
pep
given
promptli
correctli
protect
rabi
correl
presenc
rabiesspecif
virusneutr
antibodi
vna
accord
vna
titer
greater
intern
unit
per
ml
serum
reliabl
provid
protect
human
anim
current
rabiesinfect
dog
major
reason
high
incid
human
rabi
therefor
vaccin
dog
shown
costeffect
strategi
prevent
rabi
human
report
vaccin
coverag
canin
popul
effici
reduc
viru
transmiss
prevent
human
rabi
howev
despit
fact
efficaci
vaccin
readili
avail
rabi
still
high
death
rate
mainli
due
cost
access
proper
pep
treatment
current
pep
schedul
requir
multipl
inject
also
timeconsum
problem
even
pronounc
due
fact
rabvspecif
immunoglobulin
rig
expens
often
short
suppli
requir
treat
sever
exposur
creat
particular
burden
rural
region
develop
countri
suffer
highest
incid
rate
rabi
therefor
develop
altern
costeffect
vaccin
would
induc
sustain
immun
singl
dose
inocul
could
ideal
clear
viru
infect
cn
warrant
advent
revers
genet
techniqu
revolution
studi
rabv
well
negativestrand
rna
virus
greatli
advanc
understand
biolog
virus
profoundli
acceler
develop
novel
vaccin
variou
pathogen
number
excel
review
written
focus
revers
genet
negativestrand
rna
virus
biolog
rabv
rabi
vaccin
patholog
prophylaxi
rabi
review
rectifi
lack
focu
current
strategi
evalu
prevent
pep
rabi
review
place
particular
emphasi
promis
approach
use
liveattenu
andor
recombin
vaccin
platform
prevent
vaccin
innov
modal
monoclon
antibodybas
platform
small
interf
rna
sirna
interf
viru
replic
may
deserv
futur
research
rabi
treatment
also
briefli
introduc
rabi
ancient
neurolog
diseas
caus
mainli
rabi
viru
rabv
almost
invari
fatal
clinic
symptom
develop
current
rabi
continu
pose
seriou
public
health
threat
area
world
especi
develop
countri
asia
africa
estim
world
health
organ
annual
human
death
caus
rabi
bite
rabid
anim
worldwid
viru
enter
peripheri
site
exposur
subsequ
spread
central
nervou
system
cn
caus
neuron
dysfunct
like
main
caus
fatal
outcom
rabi
caus
agent
rabv
type
speci
genu
lyssaviru
famili
rhabdovirida
rabv
genom
singlestrand
negativesens
rna
approxim
kb
encod
five
structur
protein
order
nucleoprotein
n
phosphoprotein
p
matrix
protein
glycoprotein
g
rnadepend
rna
polymeras
l
negativesens
rna
genom
tightli
encapsid
n
p
l
protein
form
ribonucleoprotein
complex
respons
viru
replic
cytoplasm
within
infect
cell
rabv
g
protein
viral
protein
recent
advanc
modern
cell
cultiv
techniqu
made
feasibl
produc
highqual
rabi
vaccin
cell
cultur
import
develop
although
rabv
highli
neurotrop
lose
tissu
tropism
adapt
vitro
cultur
cell
featur
util
propag
rabv
mani
differ
cell
type
order
achiev
high
viru
yield
first
licens
human
rabi
vaccin
develop
cell
cultur
primari
hamster
kidney
cell
vaccin
creat
cultiv
virus
primari
hamster
kidney
cell
subsequ
fix
rabv
adapt
human
diploid
cell
strain
initi
use
lungderiv
cell
line
subsequ
switch
fetal
lung
cell
strain
produc
human
diploid
cell
vaccin
first
purifi
concentr
lyophil
rabi
vaccin
human
diploid
cell
vaccin
elicit
significantli
higher
immunogen
caus
much
fewer
advers
effect
compar
rabi
vaccin
therefor
recommend
gold
standard
refer
vaccin
howev
lower
viru
yield
higher
product
cost
make
human
diploid
cell
vaccin
difficult
scale
gener
unafford
develop
countri
major
human
death
rabi
occur
altern
cell
cultur
vaccin
purifi
duckchick
embryo
cell
vaccin
develop
prove
effect
human
diploid
cell
vaccin
commonli
use
human
rabi
prevent
worldwid
nevertheless
primari
cultur
cell
inher
limit
capac
divid
technic
difficult
adapt
largescal
industri
cultiv
vaccin
manufactur
reason
vero
cell
line
use
produc
purifi
vero
cell
rabi
vaccin
vero
cell
cultiv
easili
scale
viru
titer
produc
vero
cell
gener
higher
primari
cultur
cell
importantli
vero
cell
line
long
histori
use
vaccin
without
safeti
concern
advantag
vero
cell
significantli
reduc
cost
rabi
vaccin
product
make
rabi
vaccin
afford
develop
countri
undoubtedli
vero
cell
continu
one
common
popular
media
human
rabi
vaccin
product
futur
unlik
vaccin
howev
rabi
vaccin
design
prophylact
administ
primarili
postexposur
manner
due
extrem
high
mortal
rabi
inactiv
rabi
vaccin
approv
human
rabi
control
classic
inactiv
rabi
vaccin
fulli
protect
rabi
administ
preexposur
promptli
postexposur
gener
given
multipl
dose
rabv
enter
cn
symptom
develop
exampl
case
delay
vaccin
inocul
inactiv
vaccin
complet
ineffect
contrast
inactiv
viral
vaccin
induc
cell
humor
respons
liveattenu
virus
could
induc
cell
humor
respons
also
trigger
cell
respons
well
innat
immun
respons
play
pivot
role
cellular
immun
respons
viral
infect
addit
liveattenu
virus
could
produc
econom
trigger
longlast
immun
singl
dose
partial
account
wide
use
vaccin
mani
diseas
smallpox
polioviru
measl
characterist
liveattenu
virus
make
ideal
candid
futur
rabi
vaccin
improv
efficaci
potenc
fulfil
ultim
goal
onedos
rabi
vaccin
human
pep
especi
benefit
infect
individu
would
otherwis
die
rabi
current
number
recombin
liveattenu
virus
belong
sever
famili
investig
potenti
vaccin
rabi
control
tabl
encourag
result
obtain
experiment
set
could
pave
way
futur
rabi
therapi
sinc
first
recoveri
infecti
rabv
clone
complementari
dna
cdna
use
revers
genet
techniqu
schnell
et
al
numer
studi
perform
manipul
rabv
genom
combat
rabi
import
find
virul
wildtyp
rabv
attenu
serial
passag
cultur
cell
subsequ
studi
identifi
molecular
basi
attenu
phenotyp
recent
studi
shown
liveattenu
rabv
activ
pathogen
rabv
evad
host
innat
immun
respons
cn
demonstr
coadministr
attenu
rabv
street
rabv
protect
anim
rabi
partial
explain
fact
infect
liveattenu
rabv
initi
stimul
express
neuron
cytokin
attract
infiltr
inflammatori
cell
cn
boost
induct
proinflammatori
chemokinescytokin
cn
cascad
eventu
lead
regul
express
tight
junction
protein
bloodbrain
barrier
bbb
thu
enhanc
bbb
permeabl
demonstr
enhanc
bbb
permeabl
play
crucial
role
immun
clearanc
rabv
cn
allow
infiltr
immun
effector
cell
vna
peripheri
cn
clear
virus
failur
open
bbb
lead
lethal
outcom
street
rabv
infect
interestingli
recent
studi
demonstr
live
replicationdefici
rabvbas
vaccin
induc
celldepend
independ
b
cell
activ
direct
infect
stimul
b
cell
might
account
rapid
potent
induct
earli
protect
immun
respons
live
rabvbas
vaccin
studi
indic
might
possibl
develop
therapeut
base
liveattenu
rabv
treatment
clinic
rabi
increas
immunogen
address
safeti
issu
associ
liveattenu
rabvbas
vaccin
sever
strategi
employ
construct
replicationdefici
viru
target
specif
viral
gene
insert
proinflammatori
cytokineschemokin
viral
backbon
use
revers
genet
techniqu
engin
rabv
genom
strategi
briefli
summar
tabl
gener
liveattenu
recombin
rabv
vaccin
safe
even
immunocompromis
mice
also
elicit
high
vna
titer
prompt
earli
immun
respons
rabv
infect
exampl
recombin
rabv
express
granulocytemacrophag
colonystimul
factor
gmcsf
gene
payload
prevent
mice
develop
rabi
administ
intracerebr
dose
pfu
late
five
day
postinocul
note
sinc
viral
pathogen
includ
rabv
complex
antigen
structur
compris
differ
protein
like
contribut
induct
protect
immun
respons
liveattenu
rabv
probabl
promis
candid
human
well
anim
moreov
efficaci
vaccin
use
specif
rabv
strain
correl
directli
phylogenet
relationship
vaccin
strain
circul
viru
strain
specif
rabv
strain
close
phylogenet
relat
street
isol
circul
region
might
preferenti
select
rabi
vaccin
develop
given
area
hand
although
liveattenu
rabv
vaccin
superior
efficaci
costeffect
preand
postexposur
prophylaxi
rabi
compar
convent
inactiv
rabi
vaccin
liveattenu
rabv
vaccin
met
wide
accept
major
concern
safeti
ie
potenti
risk
residu
virul
toxic
associ
liveattenu
vaccin
might
caus
local
reaction
allerg
respons
neurolog
complic
especi
immunecompromis
host
furthermor
possibl
live
vaccin
might
revert
pathogen
wildtyp
even
recombin
live
agent
result
novel
pathogen
agent
rule
addit
concern
stabil
liveattenu
rabv
vaccin
consid
high
temperatur
might
inactiv
degrad
liveattenu
rabv
vaccin
need
develop
appropri
stabil
prevent
inactiv
live
vaccin
util
cold
chain
storag
transport
studi
focu
analyz
effect
combin
strategi
order
maxim
antirabi
efficaci
liveattenu
rabv
vesicular
stomat
viru
vsv
prototyp
speci
rhabdovirida
one
best
studi
anim
virus
although
rabv
vsv
highli
similar
genom
composit
biolog
rabv
vsv
quit
differ
rabv
prototyp
neurotrop
viru
caus
fatal
diseas
human
anim
vsv
arthropodborn
viru
primarili
affect
rodent
cattl
pig
hors
infect
wildtyp
vsv
nonleth
manifest
mild
symptom
importantli
preexist
immun
vsv
human
popul
gener
low
vsv
infect
human
essenti
asymptomat
limit
agricultur
laboratori
worker
similar
rabv
numer
strategi
gene
delet
perform
engin
vsv
genom
order
increas
immunogen
decreas
potenti
pathogen
along
gene
delet
gene
mutat
gene
arrang
greatli
advanc
use
vsv
viral
vector
numer
problemat
viral
pathogen
interestingli
studi
perform
investig
efficaci
use
vsv
engin
express
rabv
g
protein
protect
rabi
given
wide
applic
vsv
vaccin
vector
pathogen
virus
believ
vsv
might
repres
ideal
candid
rabi
control
parainfluenza
viru
type
previous
known
simian
viru
nonseg
negativestrand
rna
viru
genom
kb
size
belong
rubulaviru
genu
paramyxovirida
famili
shown
infect
broad
spectrum
cell
line
without
signific
cytopath
effect
support
growth
differ
cell
line
obtain
high
viral
titer
importantli
kennel
cough
vaccin
contain
live
use
dog
year
without
signific
safeti
concern
anim
human
associ
human
diseas
report
featur
suggest
could
use
good
vaccin
vector
human
rabi
control
also
demonstr
express
rabv
g
gene
elicit
robust
immun
respons
protect
lethal
rabv
challeng
display
dosedepend
protect
manner
singl
dose
pfu
suffici
protect
administ
via
intranas
rout
protect
achiev
mice
vaccin
pfu
via
intramuscular
rout
furthermor
mice
vaccin
oral
still
show
signific
surviv
rate
protect
inocul
singl
dose
pfu
importantli
protect
mice
late
six
day
rabv
challeng
protect
inocul
singl
dose
pfu
via
intramuscular
rout
result
demonstr
promis
vaccin
candid
prevent
control
rabi
newcastl
diseas
viru
ndv
member
genu
avulaviru
famili
paramyxovirida
one
viru
vector
clinic
evalu
oncolyt
cancer
therapi
gene
therapi
immun
stimul
one
obviou
advantag
ndv
bird
viru
adapt
avian
immun
system
usual
infect
mammal
due
host
rang
restrict
sever
studi
shown
recombin
ndv
express
appropri
protect
antigen
provid
good
protect
mani
pathogen
infect
influenza
viru
human
respiratori
syncyti
viru
hrsv
sever
acut
respiratori
syndrom
sar
result
indic
ndv
promis
vaccin
vector
human
mammal
recombin
ndv
construct
express
g
gene
era
strain
rlrvg
evalu
abil
serv
vaccin
rabi
shown
rlrvg
grow
high
titer
cultur
cell
egg
infect
dosesml
allanto
fluid
express
rabv
g
chang
pathogen
vector
viru
furthermor
intramuscular
vaccin
rlrvg
induc
substanti
level
vna
product
provid
complet
protect
challeng
circul
rabv
importantli
rlrvg
induc
strong
longlast
protect
immun
respons
rabi
dog
cat
low
vaccin
dose
egg
infect
dose
complet
protect
dog
challeng
street
rabv
year
result
demonstr
ndvvector
vaccin
util
induc
longlast
system
protect
immun
rabi
anim
human
highrisk
area
control
rabi
infect
open
read
frame
viru
orfv
belong
parapoxviru
genu
poxvirida
famili
due
restrict
host
rang
sheep
goat
skin
tropism
infect
absenc
system
viru
spread
even
immunocompromis
individu
intraven
inject
high
viru
dose
shortterm
vector
specif
immun
robust
rapid
stimul
innat
immun
respons
site
infect
orfv
emerg
novel
viru
vector
system
express
differ
foreign
antigen
vaccin
candid
pathogen
virus
shown
vero
cell
cultureadapt
apathogen
orfv
strain
express
rabv
g
protein
correctli
present
rabv
g
protein
surfac
infect
cell
without
need
replic
product
infecti
recombin
orfv
furthermor
one
singl
immun
stimul
high
titer
rabvspecif
vna
mice
cat
dog
singl
intramuscular
inocul
pfu
complet
protect
mice
intracrani
challeng
high
lethal
dose
virul
rabv
strain
result
demonstr
orfv
valuabl
viru
vector
use
vaccin
rabi
control
treatment
futur
vaccinia
viru
larg
complex
envelop
doublestrand
dna
viru
belong
orthopoxviru
genu
poxvirida
famili
similar
poxvirus
vaccinia
viru
replic
uniqu
exclus
cytoplasm
infect
cell
vaccinia
viru
infect
gener
mild
typic
asymptomat
healthi
individu
famou
applic
vaccinia
viru
modern
vaccinolog
success
use
vaccinia
viru
erad
smallpox
mileston
fight
infecti
diseas
histori
mankind
vaccinia
viru
still
use
liveviru
vaccin
smallpox
today
sever
recombin
poxvirus
licens
use
vaccin
numer
pathogen
infect
includ
rabi
first
recombin
poxviru
licens
use
vaccin
recombin
vaccinia
viru
copenhagen
strain
express
rabv
g
gene
insert
poxviru
thymidin
kinas
gene
vrg
suggest
oral
rabi
vaccin
may
effect
strategi
rabi
elimin
program
domest
wildlif
anim
live
viru
vaccin
vrg
one
two
vaccin
rabv
strain
success
use
oral
bait
control
rabi
wild
anim
red
fox
raccoon
coyot
north
america
western
europ
howev
vrg
fail
induc
adequ
protect
skunk
dog
administr
oral
singl
dose
moreov
vrg
associ
sever
skin
inflamm
human
occasion
contact
bait
anoth
drawback
vrg
preexist
vaccinationinduc
vector
immun
could
inhibit
gener
suffici
antirabi
immun
respons
altern
safer
highli
attenu
hostrestrict
variant
vaccinia
viru
modifi
vaccinia
viru
ankara
mva
strain
develop
serial
passag
primari
chick
embryo
fibroblast
cell
cultur
unfortun
recombin
mva
express
rabv
g
gene
shown
less
immunogen
vrg
two
log
titer
recombin
mva
requir
elicit
equival
vna
respons
laboratori
mice
howev
recombin
mva
elicit
adequ
protect
immun
respons
dog
raccoon
oral
administr
poxvir
vector
canarypox
viru
raccoon
poxviru
capripoxviru
fowlpox
viru
also
use
gener
recombin
live
vaccin
rabi
vaccin
gener
limit
thu
ideal
use
rabi
vaccin
adenovirus
famili
nonenvelop
doubl
strand
dna
virus
icosahedr
nucleocapsid
pathogen
broad
rang
vertebr
host
reptil
bird
mammal
amphibian
adenoviru
vector
shown
highli
efficaci
capabl
induc
strong
antibodi
cell
respons
make
ideal
candid
gene
therapi
vaccin
develop
human
adenovirus
far
best
character
applic
adenovirus
gene
transfer
studi
vaccin
vector
carri
vector
base
replicationdefect
human
serotyp
essenti
gene
delet
express
rabv
g
protein
adrabgp
construct
test
mice
mice
immun
birth
adrabgp
develop
antibodi
rabv
protect
subsequ
lethal
challeng
furthermor
immun
respons
elicit
adrabgp
impair
matern
immun
suggest
adrabgp
could
use
immun
shortli
birth
shown
adrabgp
induc
high
titer
vna
rabi
dog
previous
immun
convent
rabi
vaccin
also
known
onrab
replicationcompet
vector
insert
rabv
g
gene
region
thu
render
viru
replic
defect
demonstr
induc
high
level
vna
protect
rabi
importantli
immunogen
demonstr
signific
protect
bait
skunk
raccoon
vrg
vaccin
show
limit
efficaci
besid
number
adenovirus
avirul
canin
adenoviru
chimpanze
adenoviru
vector
serotyp
also
term
avian
adenoviru
celo
viru
also
investig
use
rabi
vaccin
recombin
adenovirus
gener
elicit
robust
vna
product
provid
adequ
protect
rabi
result
demonstr
recombin
adenovirusbas
vector
warrant
consider
human
rabi
control
particularli
oral
vaccin
wildlif
anim
pseudorabi
viru
prv
also
known
suid
herpesviru
aujeszki
diseas
viru
member
herpesviru
type
viru
belong
varicelloviru
genu
alphaherpesvirina
subfamili
herpesvirida
famili
genom
prv
linear
doublestrand
dna
enclos
within
protect
icosahedr
nucleocapsid
prv
main
caus
aujeszki
diseas
swine
endem
part
world
recent
prv
attract
much
attent
diseas
control
swine
agricultur
also
use
model
studi
herpesviru
biolog
neuron
pathway
addit
vector
base
prv
develop
deliveri
viral
antigen
improv
efficaci
vaccin
pig
pathogen
recombin
prv
express
rabv
g
gene
rprvegfprgp
construct
analyz
efficaci
protect
rabi
shown
growth
rate
rprvegfprgp
compar
parent
prv
strain
rprvegfprgp
safe
dog
oral
intramuscular
rout
inocul
induc
protect
immun
respons
pseudorabi
rabi
dog
via
singl
oral
inocul
pfu
vna
produc
rprvegfprgp
maintain
six
month
result
demonstr
prv
may
serv
altern
live
vector
develop
oral
rabi
vaccin
dog
autographa
californica
multipl
nucleopolyhedroviru
acmnpv
type
speci
baculovirida
famili
envelop
doublestrand
dna
virus
specif
pathogen
arthropod
mainli
affect
insect
order
lepidoptera
hymenoptera
diptera
due
strict
host
specif
baculovirus
probabl
benefici
virus
human
use
bioinsecticid
forestri
agricultur
pest
vector
viruslik
particl
express
surfac
display
techniqu
importantli
baculovirusinsect
express
system
one
popular
robust
eukaryot
express
system
heterolog
gene
express
insect
cell
recombin
acmnpv
express
rabv
g
gene
construct
control
acmnpv
polyhedrin
immedi
earli
cmv
promot
vitro
studi
demonstr
bvrvgrvg
induc
syncytium
format
insect
cell
display
effici
gene
deliveri
mammalian
cell
importantli
mice
intramuscularli
immun
bvrvgrvg
develop
high
level
vna
complet
protect
lethal
rabv
challeng
result
demonstr
baculoviru
use
altern
strategi
develop
safe
efficaci
vaccin
rabi
although
liveattenu
virusbas
vaccin
repres
promis
approach
rabi
control
treatment
novel
modal
also
investig
potenti
role
rabi
treatment
protein
peptid
vaccin
nucleic
acidbas
vaccin
rna
interfer
rnai
rig
coupl
bbb
permeabl
enhanc
agent
monocyt
chemotact
still
anoth
promis
approach
bispecif
antibodi
bsab
one
arm
target
receptor
involv
receptormedi
transcytosi
pathway
brain
anoth
one
target
rabv
g
protein
thu
potenti
enabl
effici
transport
antibodi
across
bbb
order
clear
rabv
cn
sever
studi
investig
efficaci
g
protein
purifi
infect
cell
rabi
protect
base
fact
rabv
g
protein
major
determin
viral
pathogen
also
major
protect
antigen
respons
induc
protect
immun
rabi
one
studi
rabv
g
protein
engin
yeast
system
yeast
extract
contain
rabi
g
protein
protect
guinea
pig
lethal
rabv
challeng
administ
intramuscularli
fail
protect
mice
via
lethal
intracerebr
challeng
anoth
studi
sakamoto
et
al
show
rabi
g
protein
express
yeast
process
correctli
therefor
poorli
immunogen
might
ascrib
structur
complex
multimer
propens
g
protein
mention
baculovirusexpress
g
protein
insect
cell
found
antigen
conserv
immunogen
mice
provid
protect
raccoon
lethal
challeng
street
rabv
via
repeat
oral
immun
g
proteincontain
cell
lysat
furthermor
research
use
plant
maiz
tobacco
express
rabv
g
protein
obtain
socal
edibl
vaccin
although
form
vaccin
induc
detect
vna
respons
protect
challeng
mice
upon
ingest
thu
potenti
gener
low
cost
sever
limit
obviou
includ
immunogen
stabil
vaccin
fruit
degrad
vaccin
stomach
intestin
immun
respons
therefor
despit
fact
edibl
vaccin
attract
appeal
option
much
work
must
conduct
becom
viabl
option
altern
rabi
vaccin
overal
protein
subunit
vaccin
often
poorli
immunogen
induc
limit
immun
respons
also
notic
therapeut
use
vaccin
given
inject
express
protein
must
extens
purifi
would
like
render
approach
costineffect
besid
protein
subunit
vaccin
peptid
vaccin
also
conduct
test
efficaci
rabi
protect
number
antigen
epitop
identifi
rabv
g
protein
peptid
mimick
epitop
synthes
shown
peptid
express
linear
epitop
g
protein
name
locat
aa
g
protein
induc
strong
humor
immun
respons
absenc
carrier
protein
immun
goat
mount
high
antibodi
titer
show
strong
avid
peptid
purifi
surfac
g
protein
howev
antibodi
produc
weakli
neutral
rabv
carri
epitop
fail
neutral
escap
mutant
carri
singl
point
mutat
epitop
peptid
mimotop
g
protein
identifi
random
constrain
hexapeptid
phage
display
librari
use
neutral
human
antirabv
igg
antibodi
shown
match
antigen
site
iii
g
protein
mimotop
abl
interact
human
antirabv
igg
antibodi
dosedepend
manner
subcutan
administr
rabv
g
site
iii
mimotop
induc
antirabv
gspecif
igg
respons
mice
address
whether
mimotop
could
elicit
immun
protect
lethal
challeng
mous
model
hand
chimer
peptid
contain
antigen
determin
g
protein
amino
acid
n
protein
amino
acid
construct
fuse
coat
protein
alfalfa
mosaic
viru
tobacco
spinach
plant
recombin
viru
induc
immun
respons
mice
protect
mice
challeng
infect
follow
singl
dose
convent
rabi
viru
vaccin
three
nine
individu
show
detect
level
rabvneutr
antibodi
indic
potenti
plant
virusbas
express
system
supplementari
oral
booster
rabi
vaccin
howev
high
variabl
g
protein
would
compromis
peptid
vaccin
induc
antibodi
specif
epitop
still
novel
approach
use
peptid
target
one
multipl
critic
step
rabv
replic
case
point
peptid
mimic
rabv
p
protein
core
compon
rabv
transcriptionrepl
complex
peptid
contain
first
amino
acid
p
protein
shown
inhibit
rabv
vsv
infect
cell
importantli
peptid
also
significantli
inhibit
viru
replic
neuron
cell
result
impli
peptid
interfer
certain
step
viral
replic
hold
promis
therapeut
approach
rabi
nextgener
vaccin
nucleic
acidbas
vaccin
drawn
much
attent
past
two
decad
gener
nucleic
acid
vaccin
base
dna
rna
encod
specif
antigen
interest
nucleic
acidbas
vaccin
possess
capabl
mimic
live
infect
express
antigen
situ
immun
without
pose
safeti
concern
induc
humor
cellular
immun
respons
therefor
wide
explor
numer
type
diseas
control
cancer
treatment
especi
circumst
vaccin
exist
replac
exist
vaccin
advantag
nucleic
acidbas
vaccin
includ
stabil
low
product
cost
eas
develop
purif
scale
product
much
simpler
compar
purifi
protein
vaccin
viral
vaccin
number
studi
conduct
evalu
efficaci
dna
vaccin
rabi
plasmid
express
rabv
g
protein
control
earli
promot
vector
test
mice
induct
rabiesspecif
immun
respons
mice
intramuscularli
immun
vector
develop
rabv
gspecif
cytolyt
cell
lymphokinesecret
helper
cell
subset
rabi
vna
fulli
protect
subsequ
lethal
rabv
challeng
pclneo
plasmid
encod
rabv
g
protein
control
cmv
promot
pgpv
construct
test
dog
beagl
intramuscularli
immun
pgpv
develop
high
vna
titer
wildtyp
rabv
lesser
extent
european
bat
lyssavirus
vaccin
dog
protect
lethal
rabv
challeng
wildtyp
dog
rabi
strain
importantli
comparison
dna
vaccin
tradit
human
diploid
cell
vaccin
monkey
show
two
approach
elicit
compar
primari
anamnest
vna
respons
vaccin
monkey
surviv
lethal
rabv
challeng
still
research
explor
use
repliconbas
selfrepl
dna
vaccin
deriv
alphaviru
sindbi
viru
improv
biosafeti
immunogen
dna
vaccin
recombin
replicon
express
rabi
g
protein
effici
induc
apoptosi
transfect
cell
import
event
enhanc
immun
respons
mice
intramuscularli
inject
repliconbas
rabi
dna
vaccin
induc
compar
humor
cellular
immun
respons
compar
commerci
cell
cultur
vaccin
better
convent
rabi
dna
vaccin
addit
repliconbas
rabi
dna
vaccin
commerci
cell
cultur
vaccin
confer
complet
protect
lethal
rabv
challeng
result
clearli
demonstr
dna
vaccin
promis
candid
rabi
control
despit
tremend
advantag
dna
vaccin
mass
vaccin
rabi
sever
drawback
use
dna
vaccin
need
investig
slow
onset
modest
induct
protect
immun
respons
upon
dna
vaccin
preclud
use
postexposur
immun
rabi
probabl
due
poor
immunogen
inadequ
uptak
dna
vaccin
cell
inocul
site
thu
multipl
immun
high
dna
dose
often
requir
produc
enough
antigen
optim
immun
respons
number
improv
made
increas
safeti
efficaci
dna
vaccin
improv
dna
uptak
electropor
use
shown
gener
compar
superior
level
immun
respons
increas
immunogen
efficaci
dna
vaccin
sever
approach
conduct
includ
use
chemic
adjuv
coadministr
plasmid
express
cytokin
modifi
target
g
protein
increas
express
level
encod
protein
coinocul
tradit
inactiv
rabi
vaccin
optim
dna
vaccin
formul
target
traffick
g
protein
lysosom
supplement
adjuv
emulsigend
endeavor
significantli
increas
immunogen
efficaci
dna
vaccin
extend
potenti
prevent
control
rabi
howev
risk
still
exist
integr
plasmid
dna
host
chromosom
toler
plasmid
dna
vector
antigen
autoimmun
gener
human
antidna
immun
respons
exampl
integr
dna
host
genom
could
result
potenti
risk
longterm
even
uncontrol
express
transgen
furthermor
integr
dna
host
genom
may
also
modifi
genet
inform
host
thu
tumorigen
therefor
much
effort
need
unravel
action
mechan
dna
vaccin
becom
broadli
use
vaccin
immunotherapi
platform
besid
dna
vaccin
sever
studi
investig
potenti
vaccin
base
rna
molecul
rabi
treatment
current
two
major
form
rna
vaccin
develop
base
autorepl
capac
messeng
rna
mrna
convent
nonamplifi
mrna
vaccin
selfamplifi
mrna
vaccin
also
term
replicon
deriv
rna
viru
vector
semliki
forest
viru
sfv
maintain
replic
activ
convent
nonamplifi
mrnabas
rabi
vaccin
shown
mrna
encod
rabv
g
gene
induc
potent
vna
antigenspecif
cell
inocul
mice
importantli
mrnabas
rabi
vaccin
protect
mice
lethal
intracerebr
challeng
infect
efficaci
compar
commerci
inactiv
rabi
vaccin
moreov
mrnabas
rabi
vaccin
also
immunogen
domest
pig
elicit
vna
level
compar
induc
full
dose
commerci
inactiv
rabi
vaccin
studi
demonstr
promis
nonrepl
mrna
rabi
vaccin
prevent
rabi
case
selfamplifi
mrnabas
rabi
vaccin
shown
recombin
sfv
carri
rna
code
rabv
g
protein
sfvrvgp
induc
high
express
level
function
trimer
rabv
g
protein
moreov
sfvrvgp
elicit
compar
level
antibodi
commerci
rabi
vaccin
effect
protein
vaccin
induc
cellular
immun
respons
initi
studi
use
nake
mrna
vaccin
much
effort
put
enhanc
deliveri
effici
potenc
rna
vaccin
allevi
degrad
rna
enhanc
cellular
uptak
method
gene
gun
electropor
liposom
cation
polym
use
obtain
improv
deliveri
system
rna
vaccin
similar
dna
vaccin
chemic
adjuv
coadministr
rna
express
specif
adjuv
investig
enhanc
immunogen
final
optim
mrna
vaccin
sever
approach
conduct
modifi
rna
molecul
directli
modif
cap
structur
untransl
translat
region
achiev
high
longterm
antigen
express
vaccin
rna
vaccin
becom
increasingli
promis
strategi
diseas
control
past
decad
compar
dna
vaccin
rna
vaccin
superior
sever
aspect
unlik
dna
vaccin
potenti
risk
integr
host
genom
vaccin
base
rna
would
elimin
concern
addit
dna
vaccin
must
deliv
transcrib
within
nucleu
express
antigen
timeconsum
may
ineffici
type
cell
nondivid
matur
myocyt
contrari
rna
vaccin
directli
translat
cytoplasm
obviat
need
deliveri
nucleu
also
lead
rapid
antigen
express
final
long
known
rna
potent
stimul
innat
immun
signal
via
pattern
recognit
receptor
tolllik
receptor
retino
acidinduc
gene
ilik
receptor
adjuv
effect
rna
stimul
host
immun
respons
although
argu
rna
gener
less
stabl
dna
turn
guarante
tight
control
immunogen
rna
vaccin
effici
limit
vectorderiv
immun
safeti
issu
due
persist
rna
attribut
rna
vaccin
make
ideal
adapt
versatil
vaccin
platform
infecti
diseas
control
interf
rna
sirna
base
therapi
sirna
also
known
short
interf
rna
silenc
rna
class
doublestrand
rna
molecul
bp
length
function
within
rnai
pathway
interfer
express
specif
gene
complementari
nucleotid
sequenc
degrad
mrna
transcript
thu
lead
disrupt
protein
translat
posttranscript
gene
silenc
due
easi
manipul
power
efficaci
induct
littl
cytopathi
sirnabas
gene
silenc
target
gene
consid
one
promis
approach
achiev
antivir
defens
variou
diseas
disord
initi
plasmid
encod
sirna
anoth
form
rnai
target
specif
rabv
gene
construct
test
antirabi
efficaci
although
plasmidbas
approach
achiev
degre
antirabi
effect
low
effici
sirna
deliveri
hinder
substanti
protect
rv
antirabi
rnai
approach
increas
deliveri
effici
viral
vector
adenovirus
lentivirus
use
express
sirna
gener
viral
vectorbas
sirna
effici
inhibit
correspond
gene
express
rabv
multipl
confer
signific
protect
lethal
rabv
challeng
silenc
effici
two
rabv
gene
highli
conserv
n
l
gene
gener
chosen
target
although
p
g
gene
also
report
antivir
potenti
still
overcom
safeti
issu
relat
viral
vector
liposom
use
deliv
sirnaencod
plasmid
significantli
increas
surviv
rabvinfect
mice
compar
nonliposomemedi
deliveri
method
anoth
promis
deliveri
method
propos
kumar
et
al
demonstr
short
peptid
deriv
rabv
g
protein
bind
acetylcholin
receptor
exclus
express
neuron
cell
enabl
transvascular
deliveri
sirna
across
bbb
brain
chimer
peptid
contain
nonam
arginin
residu
ad
carboxi
terminu
peptid
shown
bind
deliv
sirna
neuron
cell
lead
specif
gene
silenc
within
brain
mice
intraven
administr
furthermor
intraven
treatment
chimer
peptidebound
antivir
sirna
complex
provid
robust
protect
fatal
japanes
enceph
viru
challeng
mice
repeat
administr
chimer
peptidesirna
complex
induc
inflammatori
cytokin
antipeptid
antibodi
indic
chimer
peptid
provid
safe
noninvas
approach
deliveri
sirna
across
bbb
taken
togeth
result
demonstr
sirnasbas
approach
potenti
develop
new
effect
antirabi
therapi
rig
recombin
monoclon
antibodi
target
specif
epitop
g
protein
highli
effect
neutral
rabv
vitro
viru
enter
cn
essenti
compon
pep
sinc
deliv
passiv
immun
particularli
import
earli
stage
host
develop
activ
immun
vaccin
howev
viru
access
cn
antibodi
restrict
cross
immuneprivileg
bbb
neutral
viru
infect
although
theori
antibodi
could
given
intracerebr
definit
practic
therapi
hand
firmli
establish
enhanc
bbb
permeabl
requir
allow
passag
vna
cn
activ
b
cell
order
cross
bbb
releas
antibodi
situ
rabv
clearanc
mention
liveattenu
viru
could
transient
enhanc
bbb
permeabl
although
rais
safeti
concern
altern
way
use
agent
cytokin
hyperosmot
solut
enhanc
bbb
permeabl
thu
allow
antibodi
pass
bbb
enter
cn
shown
mice
intraven
administ
vna
crucial
clearanc
rabv
cn
could
prevent
develop
rabi
immunocompet
immunocompromis
mice
long
bbb
permeabl
enhanc
use
rat
breakdown
bbb
permeabl
use
hyperton
arabinos
combin
passiv
administ
virusneutr
mab
prolong
surviv
infect
rat
interestingli
mab
treatment
alon
partial
increas
surviv
rate
infect
rat
result
demonstr
simultan
administr
vna
bbb
permeabilityenhanc
agent
might
therapi
clinic
rabi
howev
consid
bbb
permeabilityenhanc
agent
might
neg
affect
function
cn
integr
uncontrol
bbb
enhanc
precaut
taken
preserv
homeostasi
avoid
ad
new
neuron
damag
cn
use
bbb
permeabilityenhanc
agent
bsab
compos
two
bind
specif
two
differ
antigen
two
differ
epitop
antigen
one
antibodi
molecul
bsab
newli
emerg
area
modern
biolog
one
promis
excit
advanc
cancer
immunotherapi
purpos
bsab
recogn
target
two
differ
antigen
simultan
thu
realiz
desir
therapeut
effect
achiev
combin
two
monospecif
antibodi
cancer
immunotherapi
one
obviou
advantag
bsab
abil
redirect
immun
effector
cell
proxim
target
tumor
cell
thu
improv
tumorkil
potenti
immun
effector
cell
prototyp
form
bsab
gener
compos
two
link
singlechain
fragment
variabl
one
target
molecul
present
immun
effector
cell
found
cell
target
tumorspecif
antigen
current
studi
report
use
bsab
treat
rabi
mention
suffici
level
vna
enhanc
bbb
permeabl
critic
clearanc
rabv
cn
liveattenu
virus
pose
safeti
concern
bbb
permeabilityenhanc
agent
caus
unwant
neurolog
complic
due
disrupt
normal
bbb
integr
ideal
approach
deliv
vna
without
alter
normal
function
bbb
endogen
bbb
receptor
involv
normal
receptormedi
transcytosi
rmt
pathway
function
transport
macromolecul
insulin
transferrin
brain
ideal
target
util
deliv
biolog
case
point
rabi
vna
deliv
cn
without
interf
normal
function
bbb
receptor
includ
two
wellcharacter
transferrin
receptor
insulin
receptor
recent
identifi
solut
carrier
heavi
chain
therefor
target
receptor
act
molecular
trojan
hors
ferri
biolog
fuse
antibodi
brain
via
rmt
consequ
bsab
rabi
treatment
could
construct
one
arm
target
one
endogen
bbb
receptor
target
rabv
g
protein
theoret
bsab
could
pass
bbb
retain
abil
neutral
rabv
cn
thu
potenti
indic
novel
therapi
rabi
treatment
futur
rabi
continu
pose
sever
burden
public
health
rank
one
fatal
diseas
caus
ten
thousand
human
death
annual
particularli
develop
countri
current
dog
remain
main
sourc
rabi
respons
almost
fatal
rabi
case
human
sinc
first
develop
rabi
vaccin
pasteur
human
rabi
vaccin
improv
refin
current
cell
cultur
rabi
vaccin
human
highli
efficaci
safe
easili
access
part
world
turn
enabl
control
rabi
region
therefor
term
rabi
exposur
long
prompt
correct
pep
administ
need
develop
rabi
vaccin
current
pep
highrisk
region
shift
pep
applic
routin
preexposur
vaccin
especi
vulner
children
old
peopl
consid
approach
expect
effect
dramat
reduc
incid
rabi
case
although
prompt
simplifi
pep
still
need
preexposur
rabi
vaccin
complet
protect
rabi
exposur
howev
rabi
remain
endem
mani
part
develop
world
resourc
appropri
pep
limit
infrastructur
facil
inadequ
importantli
awar
rabi
lack
case
inexpens
safe
effect
vaccin
urgent
need
situat
even
pronounc
given
fact
import
probabl
practic
way
control
rabi
global
mass
vaccin
dog
well
wildlif
reservoir
accomplish
goal
efficaci
oral
vaccin
given
reduc
singl
dose
develop
costeffect
contrast
steadi
improv
avail
qualiti
cell
culturederiv
rabi
vaccin
rig
consist
lack
interest
develop
antivir
therapi
patient
miss
deadlin
valid
vaccin
whose
symptom
alreadi
manifest
effect
antivir
therapi
avail
patient
death
inevit
instanc
accompani
agon
pain
fortun
recent
advanc
rabi
treatment
gener
promis
tool
prevent
erad
rabi
least
murin
nonhuman
primat
model
develop
provid
hope
realiz
goal
cure
patient
suffer
rabi
rational
rabi
therapi
rabv
may
stay
entri
site
day
week
reach
cn
caus
symptom
provid
valuabl
time
limit
control
viru
infect
develop
rabi
therapi
liveattenu
viru
base
vaccin
might
promis
success
pep
vaccin
rapidli
induc
potent
protect
immun
respons
ideal
would
time
requir
less
rig
liveattenu
virusbas
vaccin
match
requir
hold
promis
cur
concern
use
liveattenu
virusbas
vaccin
come
assumpt
regard
potenti
risk
residu
virul
toxic
instabl
revers
pathogen
wildtyp
recombin
natur
howev
develop
modern
technolog
liveattenu
virus
use
vaccin
gener
replicationdefici
restrict
pathogen
commonli
maxim
complet
abolish
system
manipul
genom
virus
theoret
highli
stabl
irrevers
virul
restor
could
effect
avoid
current
number
liveattenu
viru
base
vaccin
human
use
wide
use
current
data
firmli
demonstr
rabi
vaccin
base
liveattenu
rabv
caus
advers
event
safeti
concern
nevertheless
genet
modifi
agent
enhanc
surveil
ecolog
monitor
necessari
evalu
rel
risk
environment
releas
virus
given
possibl
recombin
genet
materi
exchang
natur
even
rare
event
develop
novel
nonvir
biolog
treatment
rabi
also
progress
rapidli
within
near
futur
increas
number
avail
rabi
biolog
especi
deeper
understand
pathogenesi
rabi
interact
viral
host
protein
advanc
led
novel
modal
base
gene
transfer
technolog
protein
subunit
peptid
vaccin
nucleic
acidbas
vaccin
small
molecul
function
interfer
replicationspread
viru
nevertheless
form
vaccin
might
result
delay
immun
respons
antigen
expressionaccumul
immunogen
effici
pep
proper
adjuv
would
probabl
need
increas
acceler
immun
respons
elicit
vaccin
howev
given
abil
elicit
potent
broad
immun
respons
excel
safeti
profil
rapid
respons
newli
emerg
pathogen
nucleic
acidbas
vaccin
especi
rna
vaccin
prospect
applic
therapeut
rabi
vaccin
promis
moreov
research
sirna
target
rabv
essenti
gene
also
gain
lot
potenti
term
delay
process
rabv
infect
allow
pep
take
effect
recent
progress
proper
deliveri
system
potenti
futur
use
sirna
also
therapeut
molecul
smallmolecul
drug
cross
bbb
rabi
treatment
furthermor
lot
interest
focus
develop
monoclon
antibodi
potenti
altern
limit
expans
rig
given
rapid
advanc
antibodi
engin
envis
near
futur
monoclon
antibodi
would
licens
adjunct
rig
novel
form
monoclon
antibodi
bsab
demonstr
power
applic
cancer
immunotherapi
warrant
investig
rabi
treatment
given
potenti
noninvas
bbb
penetr
ongo
preclin
clinic
studi
novel
approach
would
certainli
shed
light
futur
rabi
treatment
antivir
therapi
import
compon
futur
effort
develop
effect
therapi
human
rabi
never
close
control
even
cure
rabi
within
next
year
burden
human
canin
rabi
decreas
mani
develop
countri
mortal
due
rabi
effect
brought
howev
note
still
mani
open
question
rabi
therapi
futur
antirabi
therapi
develop
relev
anim
model
need
evalu
moreov
genet
antigen
divers
differ
rabv
strain
sequenc
differ
might
neg
compromis
therapi
current
rabi
intervent
mainli
focus
virus
phylogroup
futur
vaccin
develop
take
member
lyssaviru
consider
creat
vaccin
broadspectrum
protect
efficaci
panlyssaviru
vaccin
could
realiz
recombin
virus
code
g
protein
sever
lyssavirus
rabv
code
addit
gs
differ
lyssavirus
chimer
g
combin
differ
lyssavirus
thu
expect
provid
protect
member
lyssaviru
genu
moreov
rabv
infect
caus
sever
neuron
dysfunct
injuri
equal
import
amelior
neuron
damag
induc
viral
infect
well
clear
rabv
cn
complet
recoveri
rabi
lastli
import
note
promis
result
achiev
anim
model
pep
liveattenu
virusbas
rabi
vaccin
effect
even
administ
late
challeng
infect
treatment
larg
prophylact
therefor
treatment
shown
cur
anim
exhibit
clinic
sign
time
treatment
perform
current
solid
scientif
evid
cur
intervent
studi
need
investig
potenti
cur
intervent
clinic
use
futur
appropri
combin
rabi
vaccin
antivir
drug
immunotherapi
neuroprotect
therapi
could
profoundli
reshap
rabi
treatment
benefit
patient
suffer
rabi
